Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.

Manu De Rycker (Lead / Corresponding author), Irene Hallyburton, John Thomas, Lorna Campbell, Susan Wyllie, Dhananjay Joshi, Scott Cameron, Ian H. Gilbert, Paul G. Wyatt, Julie A. Frearson, Alan H. Fairlamb, David W. Gray

    Research output: Contribution to journalArticle

    78 Citations (Scopus)

    Abstract

    Visceral leishmaniasis is a neglected tropical disease with significant health impact. Current treatments are poor and there is an urgent need to develop new drugs. Primary screening assays used for drug discovery campaigns have typically used free-living forms of the Leishmania parasite to allow for high-throughput screening. Such screens do not necessarily reflect the physiological situation as the disease-causing stage of the parasite resides inside human host cells. Assessing drug sensitivity of intracellular parasites on scale has recently become feasible with the advent of high-content screening methods. Here we present a 384 well microscopy-based intramacrophage Leishmania donovani assay and compare it to an axenic amastigote system. A panel of eight reference compounds was tested in both systems as well as a human counterscreen cell line, and shows that for most clinically used compounds both axenic and intramacrophage assays report very similar results. A set of 15,659 diverse compounds was also screened in both systems. This resulted in the identification of seven new anti-leishmanial compounds and revealed a high false positive rate for the axenic assay. We conclude that the intramacrophage assay is more suited as a primary hit-discovery platform than the current form of the axenic assay and discuss how modifications to the axenic assay may render it more suitable for hit-discovery.
    Original languageEnglish
    Pages (from-to)2913-2922
    Number of pages10
    JournalAntimicrobial Agents and Chemotherapy
    Volume57
    Issue number7
    DOIs
    Publication statusPublished - Jul 2013

    Fingerprint

    Leishmania donovani
    Parasites
    Neglected Diseases
    Visceral Leishmaniasis
    Leishmania
    Drug Discovery
    Pharmaceutical Preparations
    Microscopy
    Cell Line
    Health

    Cite this

    @article{e372a7bf8d0440fca916c232fdd07e51,
    title = "Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.",
    abstract = "Visceral leishmaniasis is a neglected tropical disease with significant health impact. Current treatments are poor and there is an urgent need to develop new drugs. Primary screening assays used for drug discovery campaigns have typically used free-living forms of the Leishmania parasite to allow for high-throughput screening. Such screens do not necessarily reflect the physiological situation as the disease-causing stage of the parasite resides inside human host cells. Assessing drug sensitivity of intracellular parasites on scale has recently become feasible with the advent of high-content screening methods. Here we present a 384 well microscopy-based intramacrophage Leishmania donovani assay and compare it to an axenic amastigote system. A panel of eight reference compounds was tested in both systems as well as a human counterscreen cell line, and shows that for most clinically used compounds both axenic and intramacrophage assays report very similar results. A set of 15,659 diverse compounds was also screened in both systems. This resulted in the identification of seven new anti-leishmanial compounds and revealed a high false positive rate for the axenic assay. We conclude that the intramacrophage assay is more suited as a primary hit-discovery platform than the current form of the axenic assay and discuss how modifications to the axenic assay may render it more suitable for hit-discovery.",
    author = "{De Rycker}, Manu and Irene Hallyburton and John Thomas and Lorna Campbell and Susan Wyllie and Dhananjay Joshi and Scott Cameron and Gilbert, {Ian H.} and Wyatt, {Paul G.} and Frearson, {Julie A.} and Fairlamb, {Alan H.} and Gray, {David W.}",
    year = "2013",
    month = "7",
    doi = "10.1128/AAC.02398-12",
    language = "English",
    volume = "57",
    pages = "2913--2922",
    journal = "Antimicrobial Agents and Chemotherapy",
    issn = "0066-4804",
    publisher = "American Society for Microbiology",
    number = "7",

    }

    TY - JOUR

    T1 - Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.

    AU - De Rycker, Manu

    AU - Hallyburton, Irene

    AU - Thomas, John

    AU - Campbell, Lorna

    AU - Wyllie, Susan

    AU - Joshi, Dhananjay

    AU - Cameron, Scott

    AU - Gilbert, Ian H.

    AU - Wyatt, Paul G.

    AU - Frearson, Julie A.

    AU - Fairlamb, Alan H.

    AU - Gray, David W.

    PY - 2013/7

    Y1 - 2013/7

    N2 - Visceral leishmaniasis is a neglected tropical disease with significant health impact. Current treatments are poor and there is an urgent need to develop new drugs. Primary screening assays used for drug discovery campaigns have typically used free-living forms of the Leishmania parasite to allow for high-throughput screening. Such screens do not necessarily reflect the physiological situation as the disease-causing stage of the parasite resides inside human host cells. Assessing drug sensitivity of intracellular parasites on scale has recently become feasible with the advent of high-content screening methods. Here we present a 384 well microscopy-based intramacrophage Leishmania donovani assay and compare it to an axenic amastigote system. A panel of eight reference compounds was tested in both systems as well as a human counterscreen cell line, and shows that for most clinically used compounds both axenic and intramacrophage assays report very similar results. A set of 15,659 diverse compounds was also screened in both systems. This resulted in the identification of seven new anti-leishmanial compounds and revealed a high false positive rate for the axenic assay. We conclude that the intramacrophage assay is more suited as a primary hit-discovery platform than the current form of the axenic assay and discuss how modifications to the axenic assay may render it more suitable for hit-discovery.

    AB - Visceral leishmaniasis is a neglected tropical disease with significant health impact. Current treatments are poor and there is an urgent need to develop new drugs. Primary screening assays used for drug discovery campaigns have typically used free-living forms of the Leishmania parasite to allow for high-throughput screening. Such screens do not necessarily reflect the physiological situation as the disease-causing stage of the parasite resides inside human host cells. Assessing drug sensitivity of intracellular parasites on scale has recently become feasible with the advent of high-content screening methods. Here we present a 384 well microscopy-based intramacrophage Leishmania donovani assay and compare it to an axenic amastigote system. A panel of eight reference compounds was tested in both systems as well as a human counterscreen cell line, and shows that for most clinically used compounds both axenic and intramacrophage assays report very similar results. A set of 15,659 diverse compounds was also screened in both systems. This resulted in the identification of seven new anti-leishmanial compounds and revealed a high false positive rate for the axenic assay. We conclude that the intramacrophage assay is more suited as a primary hit-discovery platform than the current form of the axenic assay and discuss how modifications to the axenic assay may render it more suitable for hit-discovery.

    U2 - 10.1128/AAC.02398-12

    DO - 10.1128/AAC.02398-12

    M3 - Article

    C2 - 23571538

    VL - 57

    SP - 2913

    EP - 2922

    JO - Antimicrobial Agents and Chemotherapy

    JF - Antimicrobial Agents and Chemotherapy

    SN - 0066-4804

    IS - 7

    ER -